Canaccord analyst William Plovanic lowered the firm’s price target on TransMedics (TMDX) to $104 from $109 and keeps a Buy rating on the shares. The firm met with management and came away with the view that management is not expecting its next large growth inflection until Q3/25, driven by clinical trials of its next generation solution technology in both heart and liver.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMDX:
- TransMedics price target lowered to $120 from $175 at TD Cowen
- TransMedics Group call volume above normal and directionally bullish
- McDonald’s, Ford, Pfizer report Q3 earnings beats: Morning Buzz
- TransMedics price target lowered to $109 from $208 at Needham
- TransMedics price target lowered to $125 from $200 at Oppenheimer